Atomoxetine

Atomoxetine
Clinical data
Trade names	Strattera, others
Other names	(R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine
AHFS/Drugs.com	Monograph
MedlinePlus	a603013
License data	US DailyMed: Atomoxetine;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
Drug class	Norepinephrine reuptake inhibitor
ATC code	N06BA09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	63–94%
Protein binding	98%
Metabolism	Liver, via CYP2D6
Elimination half-life	4.5–25 hours
Excretion	Kidney (80%) and faecal (17%)
Identifiers
	IUPAC name (3R)-N-Methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine;
CAS Number	83015-26-3 ; as HCl: 82248-59-7;
PubChem CID	54841; as HCl: 54840;
IUPHAR/BPS	7118;
DrugBank	DB00289 ; as HCl: DBSALT001207;
ChemSpider	49516 ; as HCl: ID49515;
UNII	ASW034S0B8; as HCl: 57WVB6I2W0;
KEGG	D07473 ; as HCl: D02574;
ChEBI	CHEBI:127342 ; as HCl: CHEBI:331697;
ChEMBL	ChEMBL641 ; as HCl: ChEMBL1702;
CompTox Dashboard (EPA)	DTXSID9044297 ;
ECHA InfoCard	100.120.306
Chemical and physical data
Formula	C17H21NO
Molar mass	255.361 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC=C1)O[C@H](CCNC)C2=CC=CC=C2;
	InChI InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 ; Key:VHGCDTVCOLNTBX-QGZVFWFLSA-N ;
	(what is this?) (verify)

Atomoxetine, formerly sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS). It may be used alone or along with stimulant medication. It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time, and emotional self-regulation. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.

Common side effects of atomoxetine include abdominal pain, decreased appetite, nausea, feeling tired, and dizziness. Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression. There is a lack of data regarding its safety during pregnancy; as of 2019, its safety during pregnancy and for use during breastfeeding is not certain.

It was approved for medical use in the United States in 2002. In 2022, it was the 213th most commonly prescribed medication in the United States, with more than 1 million prescriptions.